Please login to the form below

Not currently logged in
Email:
Password:

Eyevensys

This page shows the latest Eyevensys news and features for those working in and with pharma, biotech and healthcare.

Spark set to file eye disease gene therapy next year

Spark set to file eye disease gene therapy next year

Others include Bristol-Myers Squibb-backed Eyevensys, GenSight Biologics (supported by Novartis), Oxford Biomedica, Avalanche Biotechnologies, Applied Genetic Technologies, and ReGenxbio. .

Latest news

  • Boehringer backs gene therapy firm Eyevensys Boehringer backs gene therapy firm Eyevensys

    Invests in French eye disease specialist.  . Boehringer Ingelheim has announced an equity investment in French gene therapy firm Eyevensys, which specialises in the treatment of eye diseases. ... Eyevensys was set up in 2009 and raised 1.6m in its first

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics